Back to results
US 2011/0237592 A1Published application
Substituted amido phenoxybenzamides
AssigneeBayer Schering Pharma Aktiengesellschaft
InventorsIngo Hartung, Marion Hitchcock, Knut Eis, Florian Puhler
Life of this patent
Estimating the term…
Abstract
The present invention relates to substituted amido phenoxybenzamide compounds of general formula (I): in which A, R1, R2, R3, R4, R5, R6, R7, R8, R9 and n are as defined in the claims, to pharmaceutical compositions and combinations containing said compounds, to methods of preparing said compounds, and to the use of said compounds or compositions for treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients.
Claims21
A compound of general formula (I):
- in which:
- A is a ring which is aryl or heteroaryl;
- R1 is selected from the group comprising, preferably consisting of, a halogen atom, cyclopropyl, —CF3 or —C≡C—H;
- R2 is selected from the group comprising, preferably consisting of, a hydrogen atom, a halogen atom, alkyl or cyclopropyl;
- R3 is selected from the group comprising, preferably consisting of, a hydrogen atom, alkyl, cycloalkyl or heterocycloalkyl, wherein alkyl is optionally substituted one or more times, independently from each other, with hydroxyl, —NRb1Rb2, heterocycloalkyl, a halogen atom, cyano or alkoxy;
- R4 is a halogen atom or cyano;
- R5 is a hydrogen atom or alkyl, wherein alkyl is optionally substituted with hydroxyl, cyano or an amino group;
- R6 is alkyl or heterocycloalkyl, wherein alkyl is substituted one or more times, independently from each other, with a group selected from hydroxyl, a halogen atom, alkoxy, cyano, haloalkoxy, thioalkyl, heterocycloalkyl, cycloalkyl, NRb1Rb2, NH—C(O)Rc, —C(O)ORc, —C(O)NH2, —C(O)NHRc, —C(O)N(Rc)2 or —S(O)2Rc;
- or
- R6 is a moiety selected from the group comprising, preferably consisting of, —O—, —C(O)—, —CH2—, —N(Ra)—, —N(Ra)—C(O)—, —O—C(O)—, and —N(Ra)—CH2—, said moiety being bound directly to the above-mentioned ring A, thus forming a ring fused to said ring A;
- R7 is selected from the group comprising, preferably consisting of, a hydrogen atom, a halogen atom, cyano, alkyl, cycloalkyl, heterocycloalkyl;
- R8 and R9 independently from each other are a hydrogen atom or a halogen atom;
- Ra is a hydrogen atom or C1-C6-alkyl;
- Rb1 and Rb2 independently from each other are selected from the group comprising, preferably consisting of a hydrogen atom, alkyl, cycloalkyl, heterocycloalkyl;
- or
- Rb1 and Rb2 together with the nitrogen atom to which they are attached, form a 3 to 7 membered heterocycloalkyl ring, which is optionally substituted one or more times, the same way or differently, with alkyl, a halogen atom, haloalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, alkoxy, hydroxy;
- the carbon backbone of said heterocycloalkyl ring being optionally interrupted one or more times, the same way or differently, by a member of the group comprising, preferably consisting of, NH, NRb3, an oxygen or sulphur atom, and being optionally interrupted one or more times, the same way or differently, with a —C(O)—, —S(O)—, and/or —S(O)2— group, and optionally containing one or more double bonds;
- Rb3 is selected from the group comprising, preferably consisting of a hydrogen atom, alkyl, cycloalkyl, wherein C1-C6-alkyl is optionally substituted one or more times with cycloalkyl, hydroxyl, a halogen atom, haloalkyl or alkoxy;
- Rc is alkyl or cycloalkyl;
- and
- n is an integer of 0, 1 or 2.
18 more elements
Dependencies are inferred from the claim text.